EUCTR2004-004496-10-GB进行中（未招募）1 期
A Phase 2a double blind, randomised, placebo controlled, two dose study to determine the effect of orally administered methylnaltrexone (MNTX) in preventing post-operative opiate induced constipation in patients undergoing elective orthopaedic surgery - Coated MNTX
orgine International Limited0 个研究点目标入组 0 人开始时间: 2005年3月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients over 18 years of age (race, sex and BMI irrelevant), scheduled to undergo elective hip or knee replacement surgery at Ravenscourt Park Hospital.
- •Females must be either surgically sterile as documented by medical records, postmenopausal with no periods for at least one year and an untreated postmenopausal oestradiol level of Not Detected-110 pmol/L and FSH within 21.7 - 153 IU/L (WHO 2nd IRP 78/549) or agreeable to appropriate contraception. Females of child-bearing potential must have a negative urine pregnancy test.
- •Be in good health (to include stable and/or, controlled medical conditions) determined by a medical history, electrocardiogram (12-Lead ECG), haematology, biochemistry and urinalysis.
- •Be in good health (to include stable and/or, controlled medical conditions) as determined by a medical examination by a qualified physician.
- •Have given both verbal and written informed consent to participate in the study. (Consent will be documented by the patient’s dated signature, which will be countersigned and dated by the Investigator or designee, who will have explained the nature, purpose and possible risks of the study).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who have a history of relevant constipation/ diarrhoea in the last four weeks (constipation defined as no bowel movement in one week; and diarrhoea defined as more than 3 loose bowel movements per day).
- •Patients who have any condition that precludes the use of post-operative morphine PCA (patient controlled analgesia).
- •Patients who have any condition that will make the surgery or peri/ post-operative care non-standard.
- •Patients taking any medication that is on the precluded list (opiate analgesia other than morphine for the first 24hr post-operatively; Any regular laxative use pre and post-operatively (lactulose is allowed 48hrs after surgery as rescue medication” if clinically needed), prokinetic products, IBS products)).
- •Patients who have had any abdominal operation that may interfere with stool collection.
- •Patients who have any known previous or suspected allergy or reaction to methylnaltrexone or similar drugs.
- •Patients who have participated in another study with an investigational drug or product within 3 months prior to the start of this study.
- •Patients who have, or have had a history of any clinically significant neurological (brain or nerve), gastrointestinal (stomach or bowel), renal (kidney), hepatic (liver), cardiovascular (heart, circulation or blood pressure), psychological, pulmonary (chest and lungs), metabolic, endocrine (hormone), haematological (blood) disease or any other major disorders.
- •Patients who have had a clinically significant acute illness, within 30 days preceding the start of the study.
- •Patients who have any moderate to severe colitis (inflammation of the colon) as this may prevent the absorption of study medication.
研究者
相似试验
进行中（未招募）
不适用
A phase II double blind, randomised, placebo controlled, multicentre study to assess the efficacy and safety of TA-NIC in maintaining smoking cessation when given in conjunction with Nicotine Replacement Therapy (NRT) - Maintenance of smoking cessation in smokers who have quit (TA-NIC/03)Prevention of relapse in smokers who have quit.EUCTR2005-000922-22-GBXenova Ltd440
已完成
不适用
A phase II, double blind randomised, placebo controlled study to assess the safety reactogenicity and immunogenicity of three doses of GSK Biologicals (South Africa)Vaccine/immunisationInfections and InfestationsVaccinationISRCTN86632774World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)271
进行中（未招募）
不适用
A Phase IIa double blind, randomised, placebo controlled, single centre study at the university of Leuven to assess the efficacy and tolerability of idebenone in 10 - 16 year old males with cardiac dysfunction associated with Duchenne Muscular DystrophyDuchenne Muscular DystrophyEUCTR2005-002520-33-BESanthera Pharmaceuticals LLC21
进行中（未招募）
不适用
A phase II randomised, double blind, placebo-controlled, dose finding, safety and tolerability trial of XY2405 as a treatment for traumatic brain injury - BRAIN trialEUCTR2006-002813-11-ESXytis Pharmaceuticals Sàrl400
进行中（未招募）
不适用
A study to evaluate the efficacy, safety and tolerability of CT327 ointment in subjects with mild/moderate atopic dermatitisEUCTR2012-005389-36-GBCreabilis Limited210